Online inquiry

IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (CAT#: GTTS-WQ15332MR)

This product GTTS-WQ15332MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Rheumatoid arthritis (RA) research.

Specifications
Product type	mRNA
Modified bases	Pseudo-UTP
5' Cap	Cap 0
Species	Homo sapiens
RefSeq	NM_000594.4
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	7124
UniProt ID	P01375

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15332MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ14986MR	IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	SHR-1314
GTTS-WQ8880MR	IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	IFN-alpha-REC
GTTS-WQ516MR	IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	4D11
GTTS-WQ14738MR	IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 1, Pseudo-UTP, 120 nt-poly(A))	mRNA	SGN-19A
GTTS-WQ15579MR	IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	UNII-FFX71LCS5T
GTTS-WQ9322MR	IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	IMP-321
GTTS-WQ7246MR	IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 1, Pseudo-UTP, 120 nt-poly(A))	mRNA	FP-1302
GTTS-WQ11894MR	IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	MLN-1202

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST